Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121210 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
NCT02121210 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 132 participants.
The verdict
NCT02121210, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: * To evaluate the other safety aspects of sarilumab administered as monotherapy. * To assess the exposure of sarilumab administered as monotherapy.
Interventions
- DRUG sarilumab SAR153191 (REGN88)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121210
The ClinicalTrials.gov registry entry for NCT02121210 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sarilumab SAR153191 (REGN88) is the first listed.
NCT02121210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02121210 about?
NCT02121210 is a clinical study titled "To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)". Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: * To evaluate the other safety aspects of sarilumab administered as monotherapy. * To assess the exposure of sarilumab administered as monotherapy.
What is the current status of trial NCT02121210?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2014-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02121210?
The interventions under investigation include: sarilumab SAR153191 (REGN88) (DRUG).
Who is sponsoring clinical trial NCT02121210?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.